|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
798894733 |
| 003 |
DE-627 |
| 005 |
20230905071738.0 |
| 007 |
tu |
| 008 |
141022s2014 xxu||||| 00| ||eng c |
| 020 |
|
|
|a 9781493915187
|9 978-1-4939-1518-7
|
| 035 |
|
|
|a (DE-627)798894733
|
| 035 |
|
|
|a (DE-599)GBV798894733
|
| 035 |
|
|
|a (OCoLC)951436109
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XD-US
|c XA-DE
|c XA-NL
|
| 050 |
|
0 |
|a RS201.C64
|
| 060 |
|
0 |
|a 2015 A-647
|
| 060 |
|
0 |
|a QV 786.5.T3
|
| 082 |
0 |
|
|a 615.1/9
|q LOC
|2 23
|
| 084 |
|
|
|a 15,3
|2 ssgn
|
| 084 |
|
|
|a 58.28
|2 bkl
|
| 245 |
1 |
0 |
|a Hydrophilic matrix tablets for oral controlled release
|c Peter Timmins ... eds.
|
| 264 |
|
1 |
|a New York, NY [u.a.]
|b Aapspress, Springer
|c 2014
|
| 300 |
|
|
|a IX, 326 S.
|b Ill., graph. Darst.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 490 |
1 |
|
|a AAPS advances in pharmaceutical sciences series
|v 16
|
| 500 |
|
|
|a Literaturangaben
|
| 520 |
|
|
|a This detailed volume addresses key issues and subtle nuances involved in developing hydrophilic matrix tablets as an approach to oral controlled release. It brings together information from more than five decades of research and development on hydrophilic matrix tablets and provides perspective on contemporary issues. Twelve comprehensive chapters explore a variety of topics including polymers (hypromellose, natural polysaccharides and polyethylene oxide) and their utilization in hydrophilic matrices, critical interactions impacting tablet performance, in vitro physical and imaging techniques, and microenvironmental pH control and mixed polymer approaches, among others. In one collective volume, Hydrophilic Matrix Tablets for Oral Controlled Release provides a single source of current knowledge, including sections of previously unpublished data. It is an important resource for industrial and academic scientists investigating and developing these oral controlled release formulations
|
| 650 |
|
0 |
|a Drugs
|x Controlled release
|
| 650 |
|
0 |
|a Tablets (Medicine)
|
| 650 |
|
0 |
|a Oral medication
|
| 650 |
|
0 |
|a Pharmaceutical chemistry
|
| 650 |
|
2 |
|a Delayed-Action Preparations
|
| 650 |
|
2 |
|a Tablets
|
| 650 |
|
2 |
|a Drug Compounding
|
| 650 |
|
2 |
|a Technology, Pharmaceutical
|x methods
|
| 689 |
0 |
0 |
|D s
|0 (DE-588)4045699-7
|0 (DE-627)104162406
|0 (DE-576)209066407
|a Pharmazeutische Technologie
|2 gnd
|
| 689 |
0 |
1 |
|D s
|0 (DE-588)4184308-3
|0 (DE-627)104695986
|0 (DE-576)210024798
|a Tablette
|2 gnd
|
| 689 |
0 |
2 |
|D s
|0 (DE-588)4285105-1
|0 (DE-627)104318481
|0 (DE-576)210797002
|a Hydrophiles Verhalten
|2 gnd
|
| 689 |
0 |
3 |
|D s
|0 (DE-588)4202348-8
|0 (DE-627)104464658
|0 (DE-576)210148012
|a Orale Applikation
|2 gnd
|
| 689 |
0 |
4 |
|D s
|0 (DE-588)4190018-2
|0 (DE-627)104492341
|0 (DE-576)210063882
|a Wirkstofffreisetzung
|2 gnd
|
| 689 |
0 |
|
|5 (DE-627)
|
| 700 |
1 |
|
|a Timmins, Peter
|4 oth
|
| 810 |
2 |
|
|a American Association of Pharmaceutical Scientists
|t AAPS advances in the pharmaceutical sciences series
|v 16
|9 16
|w (DE-627)674628586
|w (DE-576)9674628584
|w (DE-600)2639433-9
|x 2210-7371
|7 ns
|
| 856 |
4 |
2 |
|u http://www.gbv.de/dms/bs/toc/798894733.pdf
|m V:DE-601
|m B:DE-84
|q pdf/application
|v 2015-08-11
|x Verlag
|y Inhaltsverzeichnis
|3 Inhaltsverzeichnis
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a ISIL_DE-9
|
| 936 |
b |
k |
|a 58.28
|j Pharmazeutische Technologie
|0 (DE-627)106417622
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 615.1/9
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 1506281230
|c 00
|f --%%--
|d 2936-8082
|e --%%--
|j --%%--
|y k
|z 18-11-14
|
| 980 |
|
|
|2 69
|1 01
|x 0009
|b 150954447X
|c 00
|f UB 660
|d 660/VX 8561 T584
|e u
|j --%%--
|y z
|z 23-01-15
|
| 983 |
|
|
|2 69
|1 00
|x DE-9
|8 00
|a VX 8561
|
| 984 |
|
|
|2 20
|1 01
|x 0084
|a 84$029368082
|
| 984 |
|
|
|2 69
|1 01
|x 0009
|a 9$10179410
|
| 985 |
|
|
|2 69
|1 01
|x 0009
|a 2015.494
|
